Sydney, Australia 6 June 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Michelle Parker as Head of Clinical Operations at Clarity. Michelle has enjoyed a diverse career spanning across Nuclear Medicine/PET and pharmaceutical industries, both locally and abroad over the last 20…
Clarity Pharmaceuticals was featured in Australasian BioTechnology, the journal of Ausbiotech, Australia’s life sciences industry organisation. The article, which was written by Clarity’s Lisa Sadetskaya, discusses the issues associated with gender in the life sciences and the benefits of creating gender-diverse teams. The article features Clarity as a case study, discussing practices that encourage…
Clarity Pharmaceuticals was featured in Gamma Gazette, a journal and newsletter issued by the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), which provides a unique educational resource for all those working in the field of nuclear medicine as well as a means of publication for individual members’ research work. The article discusses…
Sydney, Australia 20 April 2018 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it was invited to give oral presentations and presentations of their posters at the upcoming 12th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB) in Melbourne. Clarity’s CEO, Dr…
Sydney, Australia 21 February 2018 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Andreas Kjaer has joined their scientific advisory board. Andreas Kjaer is a professor at the University of Copenhagen and is chief physician and head of research at the Department of…
Sydney, Australia 13 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by the St Vincent Hospital (Melbourne) Human Research Ethics Committee for the Company’s clinical trial of SARTATE™ for meningioma. Clarity filed its ethics submission for the…
Sydney, Australia 6 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully in-licensed a patent application on a Prostate Specific Membrane Antigen (PSMA) targeting agent for imaging and treating prostate cancer from the University of Melbourne. Clarity is also pleased to…
Clarity Pharmaceuticals was featured in ATSE Focus magazine, a publication issued by the Australian Academy of Technology and Engineering (ATSE), which publishes articles, reviews and letters to address national technology issues and key policy issues – such as innovation and productivity. The article highlights the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine…
Sydney, Australia 8 November 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at the Children’s Hospital at Westmead in Sydney has been completed and recruitment has commenced for its SARTATE™ Kids trial. Clarity’s SARTATE™ Kids trial is a Positron Emission Tomography (PET)…
Clarity Pharmaceuticals’ partner, the Idaho Accelerator Center at Idaho State University, was awarded the Early Stage Innovation of the Year at the 2017 Idaho Innovation Awards. This achievement was for the development of a new and efficient process for producing copper-67. This process enables copper-67 to be manufactured in sufficient quantities and at a high quality…